Literature DB >> 20699663

How does the mammalian target of rapamycin (mTOR) influence CD8 T cell differentiation?

Robert J Salmond1, Rose Zamoyska.   

Abstract

Naive T lymphocytes maintain a quiescent resting state until they encounter antigen whereupon they undergo a switch in their metabolic program in preparation for proliferation and differentiation. This activation process involves a dramatic upregulation of protein synthesis that is essential for cell growth and the differentiation of effector function. An essential regulator of protein synthesis in T cells is the mammalian target of rapamycin (mTOR), a serine/threonine kinase that regulates both the availability of amino acids and the process of cap-dependent translation. Recent data indicate that mTOR influences activation and cell fate determination in T cells. We discuss these findings in light of what is currently known about the function of mTOR and its targets in CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20699663     DOI: 10.4161/cc.9.15.12358

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  5 in total

Review 1.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Authors:  William H Chappell; Linda S Steelman; Jacquelyn M Long; Ruth C Kempf; Stephen L Abrams; Richard A Franklin; Jörg Bäsecke; Franca Stivala; Marco Donia; Paolo Fagone; Graziella Malaponte; Maria C Mazzarino; Ferdinando Nicoletti; Massimo Libra; Danijela Maksimovic-Ivanic; Sanja Mijatovic; Giuseppe Montalto; Melchiorre Cervello; Piotr Laidler; Michele Milella; Agostino Tafuri; Antonio Bonati; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli; James A McCubrey
Journal:  Oncotarget       Date:  2011-03

2.  mTOR Regulation of Glycolytic Metabolism in T Cells.

Authors:  Robert J Salmond
Journal:  Front Cell Dev Biol       Date:  2018-09-25

Review 3.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 4.  Advances in targeting signal transduction pathways.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Lin Sun; Nicole M Davis; Stephen L Abrams; Richard A Franklin; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli; Massimo Libra; Saverio Candido; Giovanni Ligresti; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Marco Donia; Ferdinando Nicoletti; Jerry Polesel; Renato Talamini; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Michele; Agostino Tafuri; Joanna Dulińska-Litewka; Piotr Laidler; Antonio B D'Assoro; Lyudmyla Drobot; Drobot Umezawa; Giuseppe Montalto; Melchiorre Cervello; Zoya N Demidenko
Journal:  Oncotarget       Date:  2012-12

5.  Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1 Signals Influence T Cell Activation Independently of Ribosomal Protein S6 Phosphorylation.

Authors:  Robert J Salmond; Rebecca J Brownlie; Oded Meyuhas; Rose Zamoyska
Journal:  J Immunol       Date:  2015-10-09       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.